EFPIA


Bayer

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of around EUR 20.0 billion (2014), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 60,700 employees (Dec 31, 2014) and is represented in more than 100 countries.

PROJECT LEADER
Dr Stefan Jaroch 
Head External Innovation Technologies, Global External Innovation & Alliances

For more information visit www.bayerpharma.com



Janssen Pharmaceutica NV

Janssen Pharmaceutica NV is a subsidiary of the Janssen Research & Development organization of the Janssen Pharmaceutical companies of Johnson & Johnson (www.jnjpharmarnd.com). We are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time. Our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas: cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, and oncology. We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships. We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.

PROJECT LEADER
Dr Peter Roevens
Senior Director

Want to get more details? Go to www.janssenrnd.com



H. Lundbeck A/S

A global pharmaceutical company with a portfolio of small molecule and antibody based therapies for treating CNS disorders. Core products improve the lives of patients with depression, Alzheimer’s disease and Parkinson’s disease and reach more than 100 countries: sales in 2014 were almost €2 billion. Lundbeck has over 6000 employees worldwide, with more than 1300 in R&D. Further novel medicines to treat diseases within neurology and psychiatry are actively sought to complement previous Lundbeck discoveries, especially those focusing on Alzheimer’s disease, Parkinson’s disease, depression and schizophrenia. The firm has generated novel and innovative small lead structures using HTS, fragment screening and de novo design, which combines with experience in specialist research and in preclinical/clinical development to deliver innovative medicines to patients.

PROJECT LEADER
Dr Klaus Bæk Simonsen
Vice President

Want to get more details? Go to www.lundbeck.com



AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.   We believe the best way we can help patients is to focus on breakthrough science in order to uncover disease mechanisms and develop novel, targeted therapies that interact with them. This is at the heart of our purpose as a company: to push the boundaries of science to deliver life-changing medicines. Today we have more than 57,000 employees, operations in over 100 countries and our innovative medicines are used by millions of patients worldwide.

PROJECT LEADER
Dr Garry Pairaudeau
Head of External Sciences

Want to get more details? Go to www.astrazeneca.com 



Merck KGaA

Merck KGaA is a leading German pharmaceutical, chemical and life science company with total revenues of €11.2 billion in 2012 and with a history that began in 1668. The Small Molecule Platform of Merck Serono (the biopharmaceutical division of Merck KGaA ) is committed to the discovery of New Chemical Entities, using a state-of-the art infrastructure for screening, compound logistics and medicinal chemistry. Screening compounds are dissolved in ultrapure DMSO, stored in single tubes under argon at -20°C and undergo limited freeze-thaw cycles. Purity requirements are >90 %. Screening employs acoustic dispensing for the delivery of compounds and almost exclusively uses 1536 well format for uHTS. The screening department is experienced with confocal phenotypic screening, and its hit characterization efforts include exclusion of compound assay interference, orthogonal confirmation and selectivity screens.

PROJECT LEADER
Dr Mirek Jurzak

Want to get more details? Go to http://www.merckgroup.com/en/index.html



Sanofi Aventis Deutschland GmbH

Sanofi Aventis is a French multinational pharmaceutical company and the world's fourth-largest by prescription sales. The company covers seven principal therapeutic areas: cardiovascular, CNS, diabetes, internal medicine, oncology, thrombosis and vaccines.  Sanofi Aventis was formed in 2004 after a merger between Aventis and Sanofi-Synthélabo. 

PROJECT LEADER
Dr Hubert Haag
Sourcing & External Opportunities Lead Identification

Want to get more details? Go to http://en.sanofi.com/



UCB

UCB is a global biopharmaceutical company with a portfolio of small molecule and antibody based therapies for the treatment of severe immune-mediated diseases and CNS disorders. The firm has approximately 9000 employees worldwide, with research and early development scientists supporting an innovative pipeline of novel therapeutics. Core products treat patients with epilepsy, rheumatoid arthritis and Parkinson’s disease. UCB invests internally, externally and via collaboration to continually improve screening capabilities, and also accesses the best external collections and technologies. Expertise covers protein families across the breadth of CNS and Immunology therapeutic areas, and the UCB screening collection reflects this. A strong fragment technology platform includes substantial investment in associated biophysical techniques and the structural biology required for fragment-led programs. More recently research has focused on antibody-guided identification of small molecule modulators of protein-protein interactions. 

PROJECT LEADER
Dr Jeremy Davis
Director Hit Discovery and Enabling Technologies

For more information visit www.ucb.com